Emmaus Life Sciences, Inc. on October 4, 2022, the Board appointed Ian Zwicker as a director of the company and as the Chair and sole member of the Audit Committee of the Board. The Board also appointed Seah H. Lim, M.D., Ph.D. as a director to fill a vacancy on the five-person Board. It is anticipated that Mr. Zwicker and Dr. Lim will be appointed to serve on one or more other standing Committees of the Board.

Mr. Zwicker, age 75, served as a director, Chair of the Compensation Committee and member of the Nominations and Governance Committee of Emmaus from the completion of merger transaction with EMI Holding, Inc. on July 17, 2019, until his retirement as a director in conjunction with Annual Meeting of Stockholders held on November 23, 2021. He had served as a director of EMI Holding, Inc. since December 7, 2015. Mr. Zwicker is the founder of Zwicker Advisory Group, an independent financial advisory consulting firm, and has been its Chief Executive Officer since 2014.

From 1981 to 1990, Mr. Zwicker served as Managing Director and held a variety of management positions at the investment banking firms of SG Cowen and Hambrecht & Quist. From 1990 to 1999, Mr. Zwicker served as Managing Director and head of worldwide technology investment banking for Donaldson, Lufkin & Jenrette Securities Corporation, and from 2000 to 2001 as the President of WR Hambrecht + Co (WRH). He was a Director of Stirling Energy Systems, Inc. from 2006 to 2012.

Mr. Zwicker was a Partner at WRH and was also Head of Capital Markets from 2013 to 2014. Dr. Lim, age 64, has more than 25 years of experience working in academia and with pharmaceutical companies in the clinical developments of products in hematology, oncology, and transplantation. He is board-certified in Internal Medicine, Hematology, and Medical Oncology and is an internationally recognized physician-investigator with extensive leadership experience and a track record of success in clinical and research and development.

Most recently, since June 2021 he has served as Chief Executive Officer of Medicovestor Bio PLC, Kuala Lumpur, Malaysia, a privately held development-stage biotechnology company. From January 2017 to December 2021, he served as a consultant to Salix Pharmaceuticals/Bausch Healthcare where he was instrumental in obtaining FDA designation of rifaximin as an orphan drug for the treatment of sickle cell disease. He also has served as a consultant to numerous big pharma" companies, including Genzyme, USA, Burroughs Wellcome, and Amgen Corporation.

Since October 2021, he has served as Associate Director, Allogenic Stem Cell Transplant and Director of the Adult Sickle Cell Program at Upstate State University of New York Medical Center, Syracuse, New York. Dr. Lim has authored or co-authored numerous peer-reviewed publications and has served as Section Editor, Journal of Translational Medicine since 2016. He received his MB ChB and MD degrees from Aberdeen University School of Medicine, Aberdeen, Scotland, and Ph.D. from University of Wales College of Medicine, Cardiff, Wales.